Sr Translational Med Scientist

United States

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Healthcare, PharmaceuticalsIndustries

Requirements

Candidates must possess a Ph.D. in Molecular Biology, Genomics, Cancer Biology, Genetics, or a related field, and a minimum of 5-8 years of relevant experience in translational science, oncology, or a related field. Strong experience with circulating nucleic acids and early cancer detection methods, such as methylation, SNV/indel panels, and fragmentation, is preferred. Familiarity with novel genomic technologies and the competitive landscape is also desired.

Responsibilities

The Senior Translational Medical Scientist will partner with R&D teams, clinicians, product managers, and KOLs to identify specimen biobanks and evaluate research opportunities in early cancer detection. They will apply their expertise in genomics, molecular biology, and cancer biology to develop and execute research strategies, perform genomic analyses, lead internal knowledge management efforts, and collaborate with external partners including academic KOLs, biotech firms, and pharmaceutical companies. Additionally, they will communicate research findings, provide guidance to scientists, support Regulatory Affairs with product design and validation, and maintain compliance with HIPAA/PHI privacy standards.

Skills

Genomics

Molecular Biology

Cancer Biology

ctDNA Testing

Oncology

Translational Research

Assay Development

Biobanking

Data Analysis

Clinical Decision-Making

Research Strategy

Knowledge Management

Publication

Collaboration

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free